iBio's AI-Designed Obesity Drug Selectively Melts Fat in Primate Study

SAN DIEGO, CA – March 09, 2026 – Biotechnology firm iBio, Inc. today unveiled promising preclinical data for a novel obesity treatment, IBIO-610, that successfully reduced fat mass in obese non-human primates while largely preserving critical lean muscle. The findings, which position the drug as a potential first-in-class therapy, suggest a future where weight loss treatments could be more targeted, effective, and significantly more convenient.

The study results, announced from the company's San Diego headquarters, showed that after just two doses administered eight weeks apart, obese primates treated with IBIO-610 saw a 6.7% reduction in visceral fat—the dangerous fat surrounding internal organs—and a 5.2% decrease in total body fat. Crucially, this fat-selective loss occurred with only a minimal change in lean mass, a key differentiator from many current weight loss strategies that often result in significant muscle depletion.

"These data reinforce IBIO-610’s potential to deliver fat-selective improvements in body composition while maintaining lean mass," said Martin Brenner, DVM, Ph.D., CEO and Chief Scientific Officer of iBio, in a statement. He emphasized that the results confirm the potential of IBIO-610 as a first-in-class therapy.

The New Frontier: Quality Over Quantity in Weight Loss

For decades, the battle against obesity has been measured almost exclusively by the numbers on a scale. However, a growing body of scientific evidence underscores the importance of body composition—the ratio of fat to muscle—as a more accurate indicator of metabolic health. Aggressive weight loss through diet, exercise, or even existing medications can often lead to a loss of both fat and muscle. This loss of lean mass can be detrimental, slowing metabolism, reducing strength, and potentially leading to a rebound in weight gain, primarily as fat.

iBio's IBIO-610 aims to rewrite this paradigm. By specifically targeting fat for reduction, the drug could help patients achieve a healthier body composition, not just a lower weight. Preserving muscle is vital for maintaining metabolic rate, improving insulin sensitivity, and supporting overall physical function, which are critical for long-term health, especially in individuals with cardiometabolic conditions like type 2 diabetes.

The primate study results are a significant step in validating this approach. The observed reduction in visceral fat is particularly noteworthy. Visceral adipose tissue is strongly linked to a host of health problems, including heart disease, liver disease, and insulin resistance. A therapy that can selectively reduce this type of fat could have profound implications for preventing and treating the most severe complications of obesity.

Unlocking the Activin E Pathway

The targeted mechanism of IBIO-610 is rooted in sophisticated, cutting-edge science centered on a protein called Activin E. The drug is an antibody designed to inhibit this specific protein. Recent independent research has illuminated the central role Activin E plays in regulating how the body stores and uses energy.

Expressed primarily in the liver, Activin E levels are known to rise in response to high-fat diets. It signals through a receptor called ALK7, which is abundant in fat tissue, essentially telling fat cells to store lipids and grow larger. In effect, Activin E acts as a brake on fat breakdown (lipolysis). By blocking Activin E, IBIO-610 is designed to "release the brake," encouraging the body to burn stored fat for energy.

This therapeutic strategy is not just a company theory; it's backed by large-scale human genetic data. Genome-wide association studies (GWAS) have found that individuals with natural genetic variations that reduce Activin E function tend to have less abdominal fat and a much lower risk of developing type 2 diabetes and other metabolic issues. This provides a powerful, human-validated rationale for developing drugs that inhibit the pathway.

“These findings are consistent with body composition effects reported for therapies targeting the Activin E pathway, including human siRNA approaches,” noted Cory Schwartz, Ph.D., Director of Research and Early Development at iBio. “We believe IBIO-610’s fat-selective biology supports its potential to drive targeted fat loss while maintaining lean mass.”

AI-Powered Precision and Patient Convenience

The development of a complex antibody like IBIO-610 was accelerated by iBio's proprietary AI-driven discovery platform. In a field dominated by pharmaceutical giants, smaller biotech firms are increasingly leveraging artificial intelligence and computational biology to gain a competitive edge. These advanced platforms can analyze vast biological datasets, model complex protein interactions in three dimensions, and predict how a potential drug will behave in the body, significantly shortening discovery timelines.

Brenner highlighted the role of this technology, stating the results confirm "the capability of our AI-enabled discovery platform to address complex targets." The successful identification and early validation of IBIO-610 serve as a powerful proof-of-concept for the company's high-tech approach to tackling some of the most challenging diseases.

Perhaps the most revolutionary aspect for future patients is the drug's potential for an exceptionally convenient dosing schedule. Previously reported data from the same primate study showed IBIO-610 has an extended half-life of 33.2 days. Based on this, the company projects a potential human half-life of up to 100 days.

This durability could translate into a simple twice-yearly injection. For a chronic condition like obesity that requires lifelong management, this represents a monumental leap forward from current treatments that may require daily pills or weekly injections. Such a regimen would dramatically reduce the treatment burden on patients, likely leading to vastly improved adherence and, consequently, better long-term outcomes. This convenience factor alone could make it a highly disruptive force in the multi-billion dollar obesity drug market.

The Road from Primates to Patients

While the new data is highly encouraging, iBio's journey with IBIO-610 is still in its early stages. The non-human primate study was small and not designed for statistical significance, serving primarily as a proof-of-concept. The next critical steps involve moving the drug into human clinical trials. This multi-year process will begin with Phase 1 trials to assess safety and dosage in healthy volunteers, followed by larger Phase 2 and Phase 3 trials to prove efficacy and safety in patients with obesity.

The company plans to present the complete dataset from the primate study, including analysis of additional metabolic and mechanistic biomarkers, at scientific conferences throughout 2026. These presentations will be closely watched by investors, competitors, and the scientific community for further validation of the drug's potential. The path to FDA approval is long and fraught with risk, but the fat-selective mechanism, AI-driven design, and unprecedented dosing convenience of IBIO-610 position it as one of the most exciting next-generation candidates in the global fight against obesity and cardiometabolic disease.